for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Viveve Medical Inc

VIVE.OQ

Latest Trade

6.17USD

Change

-1.39(-18.39%)

Volume

161,614

Today's Range

5.74

 - 

7.44

52 Week Range

5.74

 - 

370.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.56
Open
7.44
Volume
161,614
3M AVG Volume
1.36
Today's High
7.44
Today's Low
5.74
52 Week High
370.00
52 Week Low
5.74
Shares Out (MIL)
0.47
Market Cap (MIL)
2.88
Forward P/E
-8.54
Dividend (Yield %)
--

Latest Developments

More

Viveve Medical Inc Board Approves A One-For-One Hundred Reverse Stock Split

Viveve Medical Signs Exclusive Distribution Partnership With Paragon Meditech In Hong Kong, China And Macau

Viveve Announces FDA 510(K) Clearance Of Viveve 2.0 Next Generation System In U.S.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Viveve Medical Inc

Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company's, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician's office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.

Industry

Medical Equipment & Supplies

Contact Info

345 Inverness Dr S Bldg B Ste 250

+1.408.5301900

https://us.viveve.com/

Executive Leadership

James G. Atkinson

Chief Business Officer and President

Scott C. Durbin

Chief Executive Officer, Director

Jim B. Robbins

Principal Financial Officer

Steven L. Basta

Director

Debora A. Jorn

Director

Key Stats

2.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.180

2017

-2.110

2018

-1.610

2019(E)

-68.750
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.22
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-157.09
Return on Equity (TTM)
-121.15

Latest News

BRIEF-Viveve Announces Pricing Of Public Offering Of Shares

* VIVEVE ANNOUNCES PRICING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK

BRIEF-Viveve Announces Proposed Public Offering Of Shares Of Common Stock

* VIVEVE ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK

BRIEF-Viveve Announces Preliminary 2017 Fourth Quarter Results

* VIVEVE ANNOUNCES PRELIMINARY 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS AND PROVIDES 2018 REVENUE GUIDANCE

BRIEF-Viveve Medical Inc files for mixed shelf of up to $50 million

* Viveve Medical Inc files for mixed shelf of up to $50 million Source text: (http://bit.ly/2zIf6EQ) Further company coverage:

BRIEF-Viveve reports Q3 loss per share $0.50

* Q3 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S

BRIEF-Viveve releases preliminary Q3 2017 financial results

* Viveve releases preliminary third quarter 2017 financial results

BRIEF-Viveve gets regulatory nod to market Viveve System in Mexico

* Viveve announces regulatory approval for Viveve System in Mexico

BRIEF-Viveve announces regulatory approval for Viveve System in Taiwan

* Viveve announces regulatory approval for Viveve System in Taiwan

BRIEF-Viveve announces additional regulatory approvals in Middle East

* Viveve announces additional regulatory approvals in Middle East

BRIEF-Viveve Medical entered into a membership unit subscription agreement with ICM

* Viveve Medical Inc - in connection with distribution agreement, company also entered into a membership unit subscription agreement with ICM

BRIEF-Viveve Medical reports Q2 loss per share $0.54

* Viveve announces second quarter 2017 financial results and strategic partnership with Incontrol Medical, Llc

BRIEF-Viveve Medical enters term loan agreement with CRG Servicing Llc

* On May 22, 2017 co entered term loan agreement with CRG Servicing Llc - SEC filing

BRIEF-Viveve secures $30 million debt financing with CRG

* Viveve medical inc - new credit facility consists of $20 million to be drawn at closing

BRIEF-Viveve Q1 loss per share $0.57

* Q1 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S

BRIEF-Viveve says expanded indication for Viveve System in South Korea

* Viveve announces expanded indication for Viveve System in South Korea

BRIEF-Viveve announces pricing of public offering of shares of common stock

* Viveve announces pricing of public offering of shares of common stock

BRIEF-Viveve Medical files for secondary offering of up to $30.0 mln

* Files for secondary offering of up to $30.0 million - SEC filing Source text: (http://bit.ly/2mbiVeK) Further company coverage:

BRIEF-Viveve reports Q4 loss per share $0.55

* Viveve reports fourth quarter and full year 2016 financial results

BRIEF-Viveve announces relocation of corporate headquarters to Denver, Colorado

* Viveve announces relocation of corporate headquarters to Denver, Colorado Source text for Eikon: Further company coverage:

BRIEF-Viveve announces additional regulatory approval in Southeast Asia

* Viveve announces additional regulatory approval in Southeast Asia

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up